The FDA published final guidance on decentralized clinical trial elements in 2024, establishing a regulatory framework that legitimizes and defines hybrid trial designs — studies where some traditionally site-based activities happen remotely, at or near a patient's home, using digital tools. The ICH E6(R3) Annex 2 is extending this framework internationally. What this means for independent research sites is that the study designs coming down the pipeline over the next three to five years will increasingly assume that sites have digital patient communication and remote monitoring capabilities.
What Decentralized Elements Actually Involve
Full decentralized trials — where patients never come to a site — remain rare for studies requiring physical procedures, laboratory draws, or imaging. Hybrid decentralized trials are more common: some visits occur at the site, others involve remote assessments, home nursing visits, or patient-reported outcomes collected through digital tools. The site remains the regulatory and coordination hub, but the proportion of patient contact happening remotely has increased.
What Sites Need to Participate in DCT Studies
Sites that can participate in hybrid DCT studies have three operational capabilities that sites without them lack: digital patient communication (automated SMS, email, and scheduling tools), remote visit coordination (video platforms and ePRO tools for remote assessments), and data systems that can ingest patient-reported outcomes from digital sources without manual transcription. Sites that already use automated SMS pre-screening, appointment scheduling, and remote communication tools are positioned for DCT participation. Sites built entirely on phone calls and paper-based processes are not.
The Competitive Implication for 2026 and Beyond
As DCT studies become a larger proportion of the industry-sponsored research portfolio, sites with digital operational infrastructure gain access to a growing segment of studies that sites without it cannot compete for. The investment in digital patient communication — which pays dividends in coordinator time savings and enrollment efficiency for traditional studies — also positions the site for a structural shift in how clinical research is conducted. That investment compounds over time in ways that are difficult to catch up with once the market has moved.